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ABCD1 transports very long-chain fatty acids (VLCFA) 
into peroxisomes. The disease manifests as inflammatory 
demyelination in the brain or and/or degeneration of cor-
ticospinal tracts, thereby resulting in spastic paraplegia, 
with the accumulation of intracellular VLCFA instead of 
protein aggregates. Using X-ALD mouse model (Abcd1− 
and Abcd1−/Abcd2−/− mice) and X-ALD patient’s fibro-
blasts and brain samples, we discovered an early engage-
ment of the UPR. The response was characterized by the 
activation of the PERK and ATF6 pathways, but not the 
IRE1 pathway, showing a difference from the models of 
AD, PD or ALS. Inhibition of PERK leads to the disruption 
of homeostasis and increased apoptosis during ER stress 
induced in X-ALD fibroblasts. Redox imbalance appears to 
be the mechanism that initiates ER stress in X-ALD. Most 
importantly, we demonstrated that the bile acid taurourso-
deoxycholate (TUDCA) abolishes UPR activation, which 
results in improvement of axonal degeneration and its asso-
ciated locomotor impairment in Abcd1−/Abcd2−/− mice. 
Abstract The activation of the highly conserved unfolded 
protein response (UPR) is prominent in the pathogenesis 
of the most prevalent neurodegenerative disorders, such 
as Alzheimer’s disease (AD), Parkinson’s disease (PD) 
and amyotrophic lateral sclerosis (ALS), which are clas-
sically characterized by an accumulation of aggregated or 
misfolded proteins. This activation is orchestrated by three 
endoplasmic reticulum (ER) stress sensors: PERK, ATF6 
and IRE1. These sensors transduce signals that induce the 
expression of the UPR gene programme. Here, we first 
identified an early activator of the UPR and investigated 
the role of a chronically activated UPR in the pathogene-
sis of X-linked adrenoleukodystrophy (X-ALD), a neuro-
metabolic disorder that is caused by ABCD1 malfunction; 
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Altogether, our preclinical data provide evidence for estab-
lishing the UPR as a key drug target in the pathogenesis 
cascade. Our study also highlights the potential role of 
TUDCA as a treatment for X-ALD and other axonopathies 
in which similar molecular mediators are implicated.
Keywords Peroxisome · ER stress · UPR · 
Oxidative stress · Neurodegeneration · TUDCA · 
Adrenoleukodystrophy
Introduction
The unfolded protein response (UPR) is a cellular stress 
reaction of the endoplasmic reticulum (ER) that is caused 
by defective protein processing [36, 82, 100]. Under physi-
ological conditions, misfolded proteins undergo the ER-
associated degradation process (ERAD), whereby the 
ER degradation-enhancing α-mannosidase-like protein 
(EDEM) forms complexes with other proteins, such as the 
protein disulphide isomerase (PDI) and the glucose-regu-
lated protein 78 (GRP78; also known as Bip) and glucose-
regulated protein 94 (GRP94) chaperones, to guide the 
translocation of misfolded proteins back to the cytosol. The 
misfolded proteins are then polyubiquitinated for targeted 
degradation by the proteasome. Through this pathway, the 
so-called UPR is activated by an aberrant accumulation of 
misfolded or unfolded proteins in the ER compartment due 
to changes in intra-reticular calcium, altered protein glyco-
sylation, energy deprivation, pathogen infection, expression 
of folding-defective proteins, or changes in redox status. 
The UPR is distinguished by the action of three ER-located 
transmembrane receptors (protein kinase RNA-like endo-
plasmic reticulum kinase (PERK), activating transcription 
factor (ATF6) and inositol requiring kinase (IRE1)), which 
regulate these events in concert.
Thus, in mammalian cells all three pathways, which are 
the so-called ER stress sensors, are involved in the UPR 
and have partially overlapping roles as described below 
[36, 82, 100]. After ER stress, unfolded proteins accumu-
late and PERK, along with additional proteins, attenuates 
mRNA translation, thereby preventing protein overload 
into the already stressed ER compartment. This transla-
tional attenuation is mediated by the phosphorylation of 
eukaryotic translation initiation factor 2 subunit α (eIF2α), 
which is essential for adaptation to cellular stress through 
the integrated stress response (ISR) process. The phos-
phorylation of eIF2α enables the preferential translation 
of UPR-dependent genes, such as the transcription fac-
tor ATF4, which drives the transcription of several critical 
genes, including the pro-apoptotic factor CHOP [36, 82, 
100].
ATF6 is a transcription factor that translocates to the 
Golgi compartment upon ER stress, where it is cleaved 
[105]. Cleaved ATF6 then enters the nucleus to activate tar-
get genes, such as GRP78, GRP94, PDI and CHOP.
Upon activation, IRE1, which is a transmembrane 
kinase/endonuclease, initiates the splicing of the X-box-
binding protein 1 (XBP1) mRNA. Spliced XBP1 (XBP1s) 
mRNA leads to the transcription of several genes that are 
involved in the UPR and ERAD to restore protein homeo-
stasis and promote cytoprotection [36, 82, 100]. In conclu-
sion, the first outcome of the UPR is protective as it helps 
maintain homeostasis. However, if the stress is not success-
fully resolved, the UPR can finally trigger apoptosis. The 
same pathways can be anti- or pro-apoptotic depending on 
the intensity, duration and cellular context of the UPR acti-
vation [36, 44, 78, 82, 100].
Unfolded protein response activation has classically 
been associated with several neurodegenerative and meta-
bolic diseases that are characterized by protein aggregates, 
including Alzheimer’s disease (AD) [41, 42, 82], Hun-
tington’s disease (HD) [95], amyotrophic lateral sclerosis 
(ALS) [81], Parkinson’s disease (PD) [82], Pick’s disease 
[47], and argyrophilic grain disease [46]. Despite several 
studies that support the interconnected nature of UPR acti-
vation, only a few reports have addressed the role of the 
ER and UPR in diseases that are driven by redox and lipid 
dyshomeostasis instead of protein misfolding [61, 91]. We 
therefore sought to explore the role of ER stress in a para-
digmatic disease of oxidative stress and lipid rather than 
protein accumulation: X-linked adrenoleukodystrophy 
(X-ALD: McKusick no. 300100) [28, 57].
X-ALD is a rare, fatal, neurometabolic disease that is 
characterized by a striking variation in clinical symptoms, 
even within the same family. The two main neurological 
phenotypes include (i) the devastating childhood cerebral 
form (CCALD), which progresses rapidly and is associ-
ated with rampant inflammatory demyelination in the brain, 
and the more common phenotype of (ii) slowly progressing 
adult-onset adrenomyeloneuropathy (AMN), which mani-
fests as a distal axonopathy of corticospinal tracts, thereby 
leading to spastic paraparesis with peripheral neuropa-
thy in some cases [26, 66]. Approximately 35% of AMN 
patients develop cerebral demyelination (cAMN) and share 
the same poor prognosis as children with cerebral ALD. All 
patients with X-ALD have mutations in the ABCD1 gene in 
Xq28, which encodes the peroxisomal adrenoleukodystro-
phy protein (ALDP or ABCD1) [26, 66]; ALDP transports 
very long-chain fatty acids (VLCFA) or VLCFA–CoA 
esters into the peroxisome for degradation by β-oxidation 
[93]. Therapeutic options are scarce, and when diagnosed 
early, the cerebral forms of the disease are only adequately 
treatable with a bone marrow transplant [1] or, recently, 
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haematopoietic stem cell gene therapy [9]. However, no 
pharmacological treatment has been proven to be beneficial 
for either form of the disease [6].
The mouse model of X-ALD, the Abcd1− mouse, devel-
ops late-onset axonopathy that resembles the most fre-
quent X-ALD phenotype, AMN [75, 76]. Using this mouse 
model and patient samples, studies by our laboratory and 
others have revealed that VLCFA-induced oxidative stress 
is an early, key pathogenic factor in X-ALD [29, 31, 35, 57, 
73, 74, 85, 94], although the exact mechanisms by which 
oxidative stress causes neurodegeneration in X-ALD are 
not entirely clear.
Oxidative stress and lipid alterations are highly inter-
twined with ER stress [61, 91, 97, 98]; we thus posited 
that UPR activation may have a role in the pathogenesis 
of X-ALD. To test this hypothesis, we determined whether 
the UPR (i) is activated in brain samples of patients who 
suffered from the cerebral forms of X-ALD (CCALD and 
cAMN), the spinal cord from the mouse model of X-ALD 
and in human X-ALD fibroblasts and (ii) is a causative 
factor of axonal degeneration, which we determined by 
assessing the effects of the ER stress inhibitor taurour-
sodeoxycholic acid (TUDCA) on the late-onset axono-
pathic phenotype that is exhibited in the X-ALD (Abcd1−/
Abcd2−/−) mouse model.
Materials and methods
Human samples
Brain tissue samples from X-ALD patients and age-
matched controls were obtained from the NIH Neuro-
BioBank: details are in the supplemental data (Supplemen-
tal Table S1).
Primary human fibroblasts were collected from healthy 
individuals and AMN patients according to the IDIBELL 
guidelines for sampling, including informed consent from 
the persons involved or their representatives. Fibroblasts 
were prepared from skin biopsies (Supplemental Table S2).
X‑ALD mice
Two X-ALD mouse models were used in this study. The 
first model, the Abcd1− mouse, is used to characterize the 
biochemical signs as it resembles adult AMN in humans 
[59, 76]. These mice exhibit metabolic signs of pathol-
ogy, including oxidative stress [29] and altered energy 
homeostasis [34]; however, the first clinical signs of 
AMN (axonopathy and locomotor impairment) appear at 
20 months [76]. The second mouse model has a double 
gene knockout of both the Abcd1 and Abcd2 transport-
ers (Abcd1−/Abcd2−/−) and is a more suitable model for 
assaying therapeutic strategies than Abcd1− mice. Indeed, 
compared with Abcd1− mice, Abcd1−/Abcd2−/−mice pre-
sent enhanced VLCFA accumulation in the spinal cord 
[75], higher levels of oxidative damage to proteins [31], 
and a more severe AMN-like pathology with an earlier 
onset at 12 months of age [30, 55, 62, 65, 75].
Male mice used for experiments were of a pure 
C57BL/6J background. Generation and genotyping for 
Abcd1− and Abcd1−/Abcd2−/− mice have been previously 
described [59, 75, 76].
For the antioxidant treatment, wild type (WT) (n = 10) 
and Abcd1− mice (n = 20) were separated into three dif-
ferent groups at 8 months of age [WT (n = 10), Abcd1− 
(n = 10) and Abcd1− mice treated with a cocktail of 
antioxidants [Vitamin E (1000 iu/kg) and α-lipoic acid 
(0.5%) in AIN-76A chow (Ssniff) and NAC (1%) in water] 
for 4 months (Abcd1− + Aox) (n = 10)] [34, 56, 57]. At 
12 months of age, mice were killed, and tissue samples 
were collected and snap-frozen in liquid nitrogen.
For the TUDCA treatment, WT (n = 10) and Abcd1− 
mice (n = 20) were separated into three different groups 
at 9 months of age [WT (n = 10), Abcd1− (n = 10) and 
Abcd1− mice treated with the bile acid TUDCA (Pro-
dotti Chimici e Alimentari SpA, Italy) for 3 months 
(Abcd1− + TUDCA) (n = 10)]. TUDCA was mixed into 
AIN-76A chow (Ssniff) at 0.4% w/w. In addition, WT 
(n = 15) and Abcd1−/Abcd2−/− mice (n = 30) were sepa-
rated into three different groups at 13 months of age [WT 
(n = 15), Abcd1−/Abcd2−/− (n = 15) and Abcd1−/Abcd2−/− 
mice treated with TUDCA (0.4% w/w) for 4 months 
(Abcd1−/Abcd2−/− + TUDCA) (n = 15)]. TUDCA had 
no effect on weight or food intake under either treatment 
protocol. The dose and duration of TUDCA, whose phar-
macokinetics have been extensively studied in rodents [14], 
was based on pilot studies using APP/PS1 mice and other 
models [11, 67].
After 4 months of treatment, locomotor experiments 
were performed for three weeks, one test a week, in order 
not to exhaust the mice. Animals were maintained under 
treatment during this period and were killed and processed 
at the end for immunohistology. For behavioural testing, 
assessment of hindlimb clasping was done by suspending 
WT and Abcd1−/Abcd2−/− mice from their tails until they 
reached a vertical position, allowing the mice to grab the 
grill of the lid of the cage with the forelimbs, as adapted 
from Dumser et al. [19]. The hindlimb reflex was analysed 
for 10 s in three consecutive trials separated by 5-min rest. 
The hindlimb reflex was scored as described in Supplemen-
tal Table S3. The treadmill and bar cross experiments were 
performed exactly as previously described [57, 64]. Mock- 
and drug-treated mice were simultaneously tested using 
these three locomotor tests (clasping, treadmill and bar 
cross) for both genotype and treatment in a blinded manner.
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All methods employed in this study were in accordance 
with the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH 
publication No. 85-23, revised 1996) and the ethical com-
mittees of IDIBELL and the Generalitat de Catalunya.
Antibodies and reagents
Detailed information on antibodies is summarized in Sup-
plemental Table S4. Hexacosanoic acid (C26:0), propidium 
iodide (PI) and tunicamycin (TM) were purchased from 
Sigma (St. Louis, MO). The PERK inhibitor GSK2606414 
was purchased from Calbiochem.
Immunofluorescence and immunohistochemistry
For all experiments, spinal cords were embedded in paraf-
fin, and serial sections (4 µm thick) were cut in a transver-
sal or longitudinal (1 cm long) plane after perfusion with 
4% paraformaldehyde.
For immunofluorescence studies, spinal cords from 3- 
and 12-month-old wild type and Abcd1− mice were incu-
bated with PDI, GRP78 or GFAP antibodies. Then, con-
focal images were acquired using a Leica TCS SL laser 
scanning confocal spectral microscope (Leica Microsys-
tems Heidelberg GmbH, Mannheim, Germany), and images 
were analysed with ImageJ 1.39 u (NIH, USA). Details of 
the immunofluorescence processing can be found in the 
supplemental experimental procedures.
Immunohistological (IHC) studies performed in WT, 
Abcd1−/Abcd2−/− and Abcd1−/Abcd2−/− mice treated with 
TUDCA were carried out with the avidin–biotin peroxidase 
method, as reported earlier [65].
The results were expressed as the mean ± SD.
Reverse transcription (RT)‑PCR analysis
Quantitative RT-PCR analysis was performed as previously 
described [65]. The expression of the genes of interest 
was analysed by Q-PCR using TaqMan® Gene Expression 
Assays (Applied Biosystems). Relative quantitation was 
carried out using the ‘Delta–Delta Ct’ (ΔΔCt) method with 
RPL0 as the endogenous control. Transcript quantification 
was performed in duplicate for each sample [65].
Cell culture and treatment
Primary human fibroblasts were cultured in DMEM (con-
taining 10% foetal bovine serum, 100 U/mL penicillin and 
100 µg streptomycin) at 37 °C in humidified 5% CO2/95% 
air. Unless otherwise stated, experiments were carried out 
with cells at 80% confluence. Cells were pretreated 1 h 
with 120 nM of PERK inhibitor GSK2606414 and then 
exposed to 2 μg/mL of tunicamycin (TM) for 48 h or 72 h. 
Cell lines were used on passages 12–18.
For viability experiments, cells were incubated with 
10 μg/mL propidium iodide for 10 min in the dark after 
treatment and then analysed with an Agilent 2100 Bioana-
lyzer (Gallios Beckman Coulter). The apoptotic cells were 
quantified with FlowJo software.
Statistical analysis
Statistical significance was assessed using the Student’s t 
test whenever two groups were compared. When analysing 
multiple groups, we used a one-way ANOVA and Tukey’s 
post hoc test to determine statistical significance. Data 
are presented as the mean ± SD (*P < 0.05; **P < 0.01; 
***P < 0.001).
Supplemental experimental procedures
Details of XBP1 mRNA processing, immunoblots and 
nuclear fractionation experiments can be found in the sup-
plemental experimental procedures.
Results
In this work, we analysed three different types of samples 
associated with X-ALD, including necropsy samples of 
brain white matter from patients with cerebral inflamma-
tory disease (CCALD and cAMN), patient fibroblasts, and 
spinal cords from the X-ALD mouse model (Abcd1− and 
Abcd1−/Abcd2−/− mice). We examined the following mark-
ers of UPR activation: (i) the induction of the ER stress 
sensors PERK, ATF6 and IRE1 and (ii) the expression of 
the UPR responsive proteins ATF4, CHOP, GADD34, 
GRP78, GRP94 and PDI.
The UPR is induced in the brain samples of patients 
with X‑ALD
Analysis of PERK phosphorylation and the P-eIF2α/eIF2α 
ratio showed an increase in PERK and eIF2α phosphorylation 
levels in the affected areas of CCALD and cAMN patients 
(Fig. 1a, b). In addition, we found a significant up-regulation 
of ATF4 levels in the affected areas of CCALD and cAMN 
patients, which correlated with an induction of CHOP in the 
affected areas of both phenotypes (Fig. 1a, b). However, for 
the same samples, no change was detected in the levels of 
GADD34, another target gene of ATF4 (Fig. 1a, b).
We assessed ATF6 activation by measuring the libera-
tion of its cleaved fragment. We showed lower cleaved-
ATF6 levels in the affected areas of the CCALD and 
cAMN brains than in the normal-appearing areas and 
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matched healthy individuals (Fig. 1a, b). Finally, immuno-
blot experiments showed that the levels of the IRE1 trans-
ducer were decreased in the affected zones of CCALD 
and cAMN brains (Fig. 1a, b). In addition, both unspliced 
and spliced XBP1 mRNA levels were similar in control, 
non-affected and affected white matter, indicating that the 
IRE1 pathway was not overactivated in X-ALD patients 
(Fig. 1c, d).
In affected white matter samples of CCALD and cAMN 
patients, ATF6 mRNA and protein shared the same pat-
tern of repression, which was correlated with decreased 
expression of GRP78, GRP94, EDEM2 and HERPUD1 
mRNA levels, (Supplemental Fig. S1a, b). However, pro-
tein expression of GRP78, GRP94 and PDI was induced in 
the same samples (Fig. 1e, f). That may be due to a lack 
of degradation of GRP78 and GRP94, which may undergo 
posttranslational modifications such as S-nitrosylation, 
as shown for PDI and GRP78 [23, 25, 26]. Under normal 
conditions, these proteins would be degraded by the protea-
some or autophagy routes, which may not occur in X-ALD 
as both systems are malfunctioning, as we have previously 
reported [8, 9].
In conclusion, the PERK pathway but not the IRE1 or 
ATF6 pathways are activated in the affected white matter 
of CCALD and cAMN patients. In the spinal cords from 
cAMN patients, we obtained similar results regarding 
PERK activation and for the ATF6 pathway which was not 
modified (Supplemental Fig. S2a, b).
Pathway‑specific regulation of the UPR in Abcd1− mice
We measured the activation of ER sensors in the spinal cords 
from Abcd1− mice early in adulthood, at three months and at 
12 months of age, well prior to disease onset, which occurs 
at 20 months. PERK phosphorylation and the P-eIF2α/
eIF2α ratio were increased in X-ALD mice at 12 months 
but not at three months of age. This PERK pathway activa-
tion was confirmed by enhanced ATF4 and CHOP levels in 
Abcd1− spinal cord tissue starting at 12 months. Finally, in 
agreement with the observations in the brain samples, we 
could not detect differences in the GADD34 levels at either 
three or 12 months of age (Fig. 2a). In contrast, here we 
detected increased levels of cleaved-ATF6 at three, and to 
a smaller extent, 12 months (Fig. 2a). To confirm the activa-
tion of the ATF6 pathway, we analysed the translocation of 
cleaved-ATF6 into the nucleus and found that cleaved-ATF6 
was increased in Abcd1− mouse spinal cord tissue at three, 
and to a lesser extent, 12 months (Fig. 2b). Since ATF6 also 
activates genes involved in the ERAD, we measured the 
expression of Edem2 and Herpud1 mRNA at 12 months 
of age. Indeed, expression of these ERAD genes appeared 
to be induced (Fig. 2c). The IRE1 transducer was not acti-
vated at three or 12 months, as demonstrated by the lack of 
spliced XBP1 (mRNA and protein) in Abcd1− mouse spinal 
cord tissue (Supplemental Fig. S3a, b).
Taken together, these data indicate that the ER stress 
response is an early phenomenon in the X-ALD mouse 
model, with a strong activation of the ATF6 pathway at 
three months of age and a later activation of the PERK and 
ATF6 but not IRE1 pathways.
Time‑dependent expression of chaperones and PDI 
in motor neurons and astrocytes of Abcd1− mice
The expression of the mRNA and protein of the chaper-
ones GRP78, GRP94 and PDI was up-regulated in the 
total extracts from the spinal cord of 3-month-old Abcd1− 
mice. At 12 months of age, the increase in PDI persisted 
(protein and mRNA), whereas GRP78 and GRP94 protein 
levels were down-regulated in the mutant mice compared 
with WT littermates (Fig. 2d). Moreover, Grp78 and Grp94 
mRNA levels were not altered and increased, respectively, 
at this age in Abcd1− mice (Supplemental Fig. S3c). To 
gain insight into the cell-type specificity of the observed 
response, we performed immunofluorescence in spinal cord 
sections. Prominent GRP78 and PDI immunostaining was 
observed in motor neurons of the Abcd1− mouse spinal 
cord at three months compared with that in the WT mice 
(Fig. 3a), which is consistent with the results obtained by 
western blot (Fig. 2d). We also detected an up-regulation 
of GRP78 expression but not an increase in PDI staining in 
astrocytes of Abcd1− mice at three months of age (Fig. 3b). 
At 12 months of age, we observed results similar to those 
obtained by western blot (i.e. decreased expression of 
GRP78 in both motor neurons and astrocytes and an induc-
tion of PDI staining in motor neurons from Abcd1− mice) 
(Fig. 3a, b).
UPR induction in fibroblasts from X‑ALD patients
The fibroblasts of X-ALD patients are a good surrogate 
cell model for dissecting disease mechanisms, as they 
recapitulate the main X-ALD hallmarks: (i) accumulation 
of VLCFA [101], (ii) higher production of free radicals of 
mitochondrial origin [58], (iii) loss of energetic homeosta-
sis [34], and (iv) altered proteostasis [55, 56]. Using this 
cell system, we sought to determine whether an induc-
tion of ER stress was detected in fibroblasts from X-ALD 
patients.
At baseline, we found increases in the levels of cleaved-
ATF6, ATF4, CHOP, and PERK and eIF2α phosphoryla-
tion, thereby mimicking the pattern of ER stress sensor 
activation in the spinal cords of 12-month-old Abcd1− mice 
(Fig. 4a). Moreover, we detected an increase in the protein 
levels of GRP94 and GRP78 in X-ALD fibroblasts com-
pared to that in the control cells at baseline (Fig. 4a).
 Acta Neuropathol
1 3
Acta Neuropathol 
1 3
Inhibition of PERK disrupts the UPR and renders the 
X‑ALD fibroblasts more susceptible to ER stress
To determine whether UPR activation was protective or 
detrimental in the X-ALD fibroblasts, we targeted the 
UPR machinery using tunicamycin (TM), which blocks 
N-linked glycosylation, inducing protein misfolding and 
the UPR. After a 48-h incubation with 2 µg/mL TM, we 
detected a slight but significant 10% increase in cell death 
in the X-ALD fibroblasts compared to that in the controls 
(Supplemental Fig. S4). In these conditions, we found that 
the PERK pathway was induced in the X-ALD fibroblasts 
as they presented significantly higher ATF4, CHOP and 
GADD34 protein levels than baseline (Fig. 4a). Of note, 
the mRNA levels of Edem2 and Herpud1 were strongly 
increased in X-ALD fibroblasts upon tunicamycin treat-
ment, suggesting that the ERAD machinery was more 
reactive to TM-induced stress (Fig. 4b). In the control 
fibroblasts, we found a similar pattern but a less intense 
response.
Since the PERK pathway appeared to be a pivotal 
player in the TM-induced UPR activation, we assessed the 
effects of the specific PERK inhibitor GSK2606414 on 
the observed UPR-induced cell death. We found that the 
PERK inhibitor induced a more premature cell death in 
X-ALD than control fibroblasts following 48 h with 2 µg/
mL TM (25% for X-ALD and 12% for controls), while 
GSK2606414 alone did not have any effect on cell death 
(Supplemental Fig. S4). At basal levels, GSK2606414 sig-
nificantly decreased PERK phosphorylation and CHOP 
levels in X-ALD fibroblasts in comparison with control 
fibroblasts.
Following 2 µg/mL TM plus 120 nM GSK2606414 
treatment for 48 h, we found a significant decrease in 
P-PERK, P-eIF2α, ATF4 and CHOP levels in X-ALD 
fibroblasts. In contrast to control fibroblasts, the only 
significant decrease was in the expression of CHOP 
(Fig. 4a). Interestingly, the GRP94 and GRP78 pro-
tein levels and Edem2 and Herpud1 mRNA levels were 
also substantially reduced with PERK inhibition in the 
X-ALD fibroblasts following 48 h TM treatment (Fig. 4a, 
b). These data suggest that PERK is a major participant 
in the transcriptional control of ATF6 and many UPR 
target genes in response to tunicamycin treatment in 
X-ALD fibroblasts, including those involved in protein 
folding, such as GRP94 or GRP78 and ERAD factors 
such as EDEM2 or HERPUD1.
Altogether, these results suggest that PERK inhibition 
blocks the induction of eIF2α phosphorylation and the 
translational control arm of the UPR, which leads to dis-
ruption of homeostasis and increased apoptosis during ER 
stress induced in X-ALD fibroblasts. Theses results were 
in accordance with the study by Teske et al. [88], show-
ing that the PERK pathway facilitates both the synthesis 
of ATF6 and trafficking of ATF6 from the ER to the Golgi 
for intramembrane proteolysis and activation of ATF6. As 
a consequence, PERK loss of function could significantly 
reduce both the translational and transcriptional phases of 
the UPR, leading to reduced protein chaperone expression 
and enhanced apoptosis.
Antioxidant treatment prevents ER stress and UPR 
induction in Abcd1− mice
We previously demonstrated that VLCFA excess produces 
free radicals, and as a consequence, early oxidative dam-
age is present in the spinal cords of Abcd1− mice [29]. 
A combination of vitamin E, α-lipoic acid and NAC effi-
ciently reduced ROS production in vitro, reversed oxidative 
damage to proteins and DNA in spinal cords, and arrested 
axonal degeneration and disability in X-ALD mice [57]. To 
determine whether UPR is regulated by redox imbalance 
in vivo, we treated the presymptomatic Abcd1− mice at 
eight months of age with the above-mentioned combination 
of antioxidants for four months. The antioxidant treatment 
normalized the levels of cleaved-ATF6, phosphorylated 
PERK, phosphorylated eIF2α, ATF4 and CHOP (Fig. 5a), 
GRP94, GRP78 and PDI (Fig. 5b) and Edem2 mRNA 
(Fig. 5c) in Abcd1− mice. These data demonstrate that oxi-
dative stress is an upstream promoter of UPR activation in 
X-ALD mice.
The bile acid TUDCA reduces the UPR activation 
in Abcd1− mice
Chemical chaperones have previously been shown to be 
effective at reducing ER stress [70, 72]. TUDCA, which is 
a well-known member of this chemical chaperone family, 
Fig. 1  a, b Induction of the UPR in CCALD and cAMN patient 
brains. Representative immunoblots for full-length ATF6, cleaved-
ATF6, total PERK, phosphorylated PERK (P-PERK), eIF2α, 
phosphorylated-eIF2α (P-eIF2α), ATF4, CHOP, GADD34 and IRE1 
levels in total lysates from controls (Ctrl) and in normal-appearing 
(NA) and affected (A) white matter from CCALD (a) and cAMN 
patients (b). XBP1 mRNA splicing analysis by RT-PCR in Ctrl 
samples and NA and A white matter from CCALD (c) and cAMN 
patients (d). Unspliced- and spliced-XBP1 mRNA corresponds to 
XBP1u mRNA and XBP1s mRNA, respectively. Representative 
immunoblots for GRP78, GRP94, and PDI levels in Ctrl samples 
and NA and A white matter from CCALD (e) and cAMN patients 
(f). Protein levels were normalized relative to γ-tubulin (γ-Tub). The 
histograms on the right (a, b) and below (e, f) show the ratio and 
the protein levels relative to control. All values are expressed as the 
mean ± SD (n = 5 by genotype and condition in a–f; *P < 0.05 and 
**P < 0. 01, one-way ANOVA followed by Tukey’s HSD post hoc 
test for a, b, e and f)
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is a unique bile acid that acts as a potent anti-apoptotic 
agent. Previous studies have shown its involvement as 
a neuroprotective agent in neurodegenerative diseases 
where the UPR is considered to be a trigger of pathogenic 
mechanisms, such as AD [17], PD [10] and ALS [106]. 
Accordingly, Abcd1− mice were fed a diet that was supple-
mented with 0.4% (wt/wt) TUDCA for three months start-
ing at nine months of age. Then, we assessed the protein 
Fig. 2  UPR induction in the X-ALD mouse model. a Representative 
immunoblots of ER stress sensors full-length ATF6, cleaved-ATF6, 
total PERK, P-PERK, eIF2α, P-eIF2α, ATF4, CHOP, GADD34 and 
IRE1 in the spinal cord tissue of Abcd1− mice and age-matched wild 
type (WT) mice at 3 and 12 months of age. The histograms on the 
right show the cleaved-ATF6, P-PERK, ATF4, CHOP, GADD34 and 
IRE1 levels normalized relative to γ-Tub and the P-PERK/PERK and 
the P-eIF2α/eIF2α ratios relative to their respective WT values. b The 
nuclear localization of cleaved-ATF6 in WT and Abcd1− mice at 3 
and 12 months of age. PARP1 was used as the control for the nuclear 
fraction (N) and aldolase A was used for the cytoplasmic fraction (C). 
The histograms on the right show the cleaved-ATF6 levels relative to 
WT values in the nuclear fractions. c Real-time RT-PCR analyses of 
Edem2 and Herpud1 mRNA at 12 months in Abcd1− mouse spinal 
cords. d Immunoblots of GRP94 and GRP78 chaperones and PDI 
in the spinal cord tissue of Abcd1− mice and age-matched wild type 
(WT) mice 3 and 12 months of age. The histograms on the right show 
the GRP94 and GRP78 chaperones and PDI levels normalized to WT 
mice and normalized relative to the γ-Tub. Values are expressed as 
the mean ± SD (n = 10 samples per genotype and condition in a, 
c and d; n = 6 samples per genotype and condition in b; *P < 0.05, 
**P < 0.01 and ***P < 0.001, Student’s t test)
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Fig. 3  The UPR is primarily induced in motor neurons and astro-
cytes during X-ALD pathogenesis. a Immunofluorescence of 
GRP78 and PDI in spinal cord sections of WT and Abcd1− mice 3 
and 12 months of age. Arrows indicate high amounts of GRP78 and 
PDI in motor neurons; Arrowheads denote motor neurons with low 
amounts of GRP78. Nuclei were counterstained with DAPI. Scale bar 
50 μm. b Dual immunolabelling of astrocytes (GFAP; green) with 
GRP78 or PDI (red) in spinal cord sections of WT and Abcd1− mice 
3 and 12 months of age. Positive cells are labelled with arrows, and 
the dashed-line stands for the limit between the grey- and white mat-
ter. Nuclei were counterstained with DAPI. The small panel below 
shows some double-positive astrocytes. Scale bar 25 μm. The his-
togram on the right represents the quantification of GRP78 and PDI 
fluorescence intensity normalized to WT mice in motor neurons 
(MNs) (a) and astrocytes (b). Values are expressed as the mean ± SD 
(n = 4 samples per genotype and condition in a and b; *P < 0.05, 
**P < 0.01 and ***P < 0.001, Student’s t test)
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Fig. 4  Inhibition of PERK 
disrupts the UPR and renders 
the X-ALD fibroblasts more 
susceptible to ER stress. a 
Representative immunoblots 
for cleaved-ATF6, total PERK, 
P-PERK, total eIF2α, P-eIF2α, 
ATF4, CHOP, GADD34, 
GRP78, GRP94 and PDI 
levels in control (Ctrl) and 
X-ALD human fibroblasts 
pretreated with or without the 
PERK inhibitor GSK2606414 
(GSK, 120 nM) for 1 h and 
then exposed to tunicamy-
cin (TM, 2 µg/mL) for 48 h. 
Protein levels were normalized 
relative to γ-tubulin (γ-Tub). 
The histograms below show 
the cleaved-ATF6, P-PERK, 
P-eIF2α, ATF4, CHOP, 
GADD34, GRP94, GRP78 and 
PDI levels normalized relative 
to γ-Tub and the P-PERK/
PERK and P-eIF2α/eIF2α 
ratios relative to their respec-
tive WT values. b Real-time 
RT-PCR analyses of Edem2 and 
Herpud1 mRNA levels in Ctrl 
and X-ALD human fibroblasts 
pretreated with or without the 
PERK inhibitor GSK2606414 
(GSK; 120 nM) for 1 h and then 
exposed to tunicamycin (TM, 
2 µg/mL) for 48 h. All values 
are expressed as the mean ± SD 
(n = 4 by genotype and condi-
tion; *P < 0.05 and **P < 0. 01, 
one-way ANOVA followed by 
Tukey’s HSD post hoc test)
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Fig. 5  Antioxidant and TUDCA treatments prevent UPR activa-
tion in the X-ALD mouse model. a, d Representative immunob-
lots for full-length ATF6, cleaved-ATF6, total PERK, P-PERK, 
total eIF2α, P-eIF2α, ATF4 and CHOP in the spinal cord tissue of 
WT mice (WT), Abcd1− mice (Abcd1−) and a antioxidant-treated 
(Abcd1− + AOX) or d TUDCA-treated (Abcd1− + TUDCA) Abcd1− 
mice at 12 months of age. GRP78, GRP94 and PDI levels were ana-
lysed in the spinal cords of WT, Abcd1− and Abcd1− + AOX mice 
(b) and Abcd1− + TUDCA mice (e) at 12 months of age. Real-time 
RT-PCR analyses of Edem2 and Herpud1 in the spinal cord tis-
sue of WT mice (WT), Abcd1− mice (Abcd1−) and c antioxidant-
treated (Abcd1− + AOX) or f TUDCA-treated (Abcd1− + TUDCA) 
Abcd1− mice at 12 months of age. In (a, b and d, e), the histo-
grams on the right show normalized UPR marker levels rela-
tive to those in untreated WT mice. All values are expressed as the 
mean ± SD (n = 10 by genotype and condition in a–d; **P < 0.01 
and ***P < 0.001, one-way ANOVA followed by Tukey’s HSD post 
hoc test)
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levels of several UPR responsive genes and ER stress sen-
sors that were previously identified as being dysregulated 
in the Abcd1− mice. The levels of cleaved-ATF6, P-PERK, 
P-eIF2α/eIF2α, ATF4 and CHOP (Fig. 5d), the levels of 
GRP78 and GRP94 and PDI (Fig. 5e) and the mRNA lev-
els of Edem2 and Herpud1 (Fig. 5f) were normalized in 
Abcd1− mice following exposure to TUDCA.
TUDCA halts axonal degeneration and locomotor 
deficit progression in Abcd1−/Abcd2−/− mice
We first observed that the UPR was also activated in 
Abcd1−/Abcd2−/− mice, following a similar pattern than 
in Abcd1− mice (Supplemental Fig. S5). To assess the pre-
clinical potential of the treatment, we treated with TUDCA 
cohorts of Abcd1−/Abcd2−/− right at disease onset, starting 
at 13 months of age until 17 months of age. As observed in 
Abcd1− mice (Fig. 5d, e), TUDCA is able to inhibit UPR 
activation in this model (Supplemental Fig. S5). We then 
evaluated axonal degeneration by semi-quantifying the 
accumulation of the axonal damage markers synaptophy-
sin and APP, the scattered myelin debris with Sudan black 
staining, the number of reactive microglia and reactive 
astrocytes and its activated-state morphology. Therefore, 
we observed that these measures were strikingly reduced 
to control levels following TUDCA treatment (Fig. 6a–q; 
Supplemental Table S5).
We next evaluated locomotor deficits in Abcd1−/
Abcd2−/− mice using clasping [19], treadmill and bar 
cross experiments [55, 57, 64, 65] after TUDCA treat-
ment. In the clasping test, the best performance score of 
each animal was used for statistical analysis. Compared 
with WT mice, Abcd1−/Abcd2−/− mice presented a lower 
score, thereby demonstrating a locomotor deficit (Fig. 6r). 
Remarkably, TUDCA treatment normalized this score. 
In the treadmill experiment, the double-knockout mice 
required longer shock times and more frequent shocks to 
run at belt speed than the WT mice, as described earlier 
[55, 57, 64, 65]. After four months of treatment, this ratio 
was indistinguishable from the WT ratio (Fig. 6s). Finally, 
in the bar cross experiments, double-knockout mutants 
often failed to maintain their balance and displayed a 
greater tendency of the hind limbs to slip off of the bar 
and longer latencies to reaching the platform at the oppo-
site end of the bar [55, 57, 64, 65]. The number of slips 
and the time necessary to cross the bar were also normal-
ized following TUDCA treatment (Fig. 6t). Overall, these 
data show that TUDCA treatment arrested the progression 
of the locomotor deficits that occur in Abcd1−/Abcd2−/− 
mice. Altogether, these results established a direct link 
between UPR activation, axonal degeneration and locomo-
tor deficits in X-ALD.
Discussion
An ER stress signature in peroxisomal disorders?
Peroxisomes are oxidative organelles present in all tis-
sues and organisms [83, 84, 102, 103] and are involved 
in several anabolic and catabolic reactions, including the 
following: the degradation of long- and very long-chain 
fatty acids (LCFA, VLCFA (C ≥ 22:0), respectively) by 
α- or β-oxidation and hydrogen peroxide detoxification 
and the synthesis of bile acids, plasmalogens and essen-
tial polyunsaturated fatty acids. The loss or malfunction 
of peroxisomes is the cause of more than 20 fatal inherited 
conditions, which are classified into two main groups: (i) 
peroxisome biogenesis (PBD) and (ii) single peroxisomal 
enzyme deficiencies. Mutations in peroxisomal proteins 
that are essential for biogenesis and membrane protein 
import (called peroxins or PEX genes) invariably lead to 
PBD, with Zellweger syndrome as the most severe mani-
festation [3, 16, 83, 102, 103], (see also http://www.peroxi-
somedb.org).
Morphological abnormalities of the ER compartment 
have been described in peroxisomal mutants, including 
Pex5−/− [18] and Abcd2−/− mice [27]. Interestingly, previ-
ous studies using Pex2−/− as a model of PBD [53, 54] or 
Acox1−/− as a model of single peroxisomal enzyme defi-
ciency [45] have shown that ER stress is induced. Indeed, 
the ER stress response in the Pex2−/− liver revealed a 
predominant activation of specific UPR branches (i.e. the 
PERK-ATF4 pathway), with increased mRNA expression 
of CHOP in conjunction with a lack or paucity of IRE1 
activation and the absence of subsequent XBP1 mRNA 
splicing [54]. The panoply of metabolic abnormalities in 
Pex2−/− liver tissue [24, 99] includes the perturbed flux 
of mevalonate, bile acids, plasmalogens, docosahexae-
noic acid (DHA, C22:6ω3) and VLCFA. Moreover, the 
same type of UPR activation (excluding IRE1) occurs 
in Acox1−/− liver tissue [45], in which the first enzyme 
of the peroxisomal β-oxidation, the so-called fatty acyl-
CoA oxidase 1, is inactive; thus, only the levels of DHA 
and VLCFA but not plasmalogens or bile acid are altered 
[2, 45, 48]. In Abcd1− mice with peroxisomal malfunc-
tions that are largely related to defective import-induced 
excessive VLCFA, we observed a similar UPR pattern with 
predominant activation of the PERK-ATF4 pathway and a 
blunted IRE1/Xbp1 response at 12 months of age.
This finding is in contrast with the phenotype in mod-
els of other leukodystrophies, such as vanishing white mat-
ter disease and Pelizaeus–Merzbacher disease (PMD), in 
which all three branches of the UPR are activated [86, 92]. 
The same observations occur in models of ALS [51], AD 
[52], tauopathies [39, 52] and synucleinopathies [12, 13].
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Fig. 6  a–q TUDCA halts 
axonal degeneration and 
locomotor disability in Abcd1−/
Abcd2−/− mice. Immunohis-
tological analysis of axonal 
pathologies performed on WT, 
Abcd1−/Abcd2−/− and TUDCA-
treated Abcd1−/Abcd2−/− mice 
(Abcd1−/Abcd2−/− + TUDCA) 
of 18 months of age. Spinal 
cord immunohistological 
sections were processed for 
a–c Iba1, d–f GFAP, g–i syn-
aptophysin, j–l APP and m–o 
Sudan black. Representative 
images for WT (a, d, g, j and 
m), Abcd1−/Abcd2−/− (b, 
e, h, k, and n), and Abcd1−/
Abcd2−/− + TUDCA (c, f, i, 
l and o) mice are shown. Bars 
25 µm. The quantification of 
synaptophysin (p) and APP (q) 
in 1-cm-long longitudinal sec-
tions of the dorsal spinal cord 
in WT, Abcd1−/Abcd2−/− and 
Abcd1−/Abcd2−/− + TUDCA 
mice at 18 m of age (n = 5 
mice per genotype and condi-
tion). The number of abnormal 
specific profiles was counted at 
every ten sections for each stain. 
At least five sections of the 
spinal cord were analysed per 
animal and per stain. Clasping 
(r), treadmill (s) and bar cross 
(t) tests were conducted on WT, 
Abcd1−/Abcd2−/− and TUDCA-
treated Abcd1−/Abcd2−/− mice 
(Abcd1−/Abcd2−/− + TUDCA) 
17 months of age. r The best 
performance score of each 
animal was used for statistical 
analysis [19]. s The latency to 
falling from the belt (time of 
shocks), the number of shocks 
received and the ratio were 
computed after 5 min. t The 
time spent to cross the bar and 
the numbers of slips of the hind 
limbs were quantified. Values 
are expressed as the mean ± SD 
(n = 5 per condition in 
a–q; n = 15 per condition in 
r–t; *P < 0.05, **P < 0.01 and 
***P < 0.001, one-way ANOVA 
followed by Tukey’s HSD post 
hoc test)
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Contribution of peroxisomal malfunction to UPR 
activation in neurodegenerative disorders
The ER and peroxisomes share not only a common evo-
lutionary history and ontogeny [40, 84, 87] but also many 
intertwined metabolic pathways, particularly the synthesis 
of the fatty acids that form the lateral chains of complex 
lipids, such as sphingolipids, phospholipids and plasmalo-
gens, which are main components of membrane lipid bilay-
ers [102]. For instance, the bile acids and DHA are partially 
synthesized in the ER before entering the peroxisome for 
the last steps of their synthesis. In addition, VLCFA are 
elongated from C16:0 in the ER [50, 68], and subsequently 
imported by ABCD1 and ABCD2 transporters into peroxi-
somes for degradation via β-oxidation [30, 93]. The last 
steps of plasmalogen biosynthesis occur in the ER, but the 
required intermediates are previously synthesized in the 
peroxisome [25, 102]. As a consequence, peroxisomal defi-
ciency results in an accumulation of toxic bile acid precur-
sors (tri-hydroxycholestanic acid (THCA) and di-hydroxy-
cholestanic acid (DHCA)) [7, 25] (Supplemental Fig. S6) 
as well as VLCFA [7], with reduced levels of protective, 
antioxidant compounds, such as DHA and plasmalogens, in 
several types of tissues from PBD patients [7].
These observations suggest that UPR activation could be 
a direct consequence of the unbalanced lipid metabolism 
that results from peroxisome malfunction.
This is supported by in vivo and in vitro studies that 
show that the activation of the UPR is directly correlated 
to a high concentration of saturated phospholipids in ER 
membranes, in the absence of protein aggregates in the 
ER lumen, as is the case for the deletion of the mediator 
subunit mdt-15, a regulator of the transcription of genes 
involved in fatty acid (FA) metabolism [43]. We thus posit 
that VLCFA excess may modify the fluidity of the ER 
lipid bilayer, as shown in model membranes [38, 104]. 
In X-ALD, this perturbation due to VLCFA excess has 
recently been speculated to occur in the inner mitochon-
drial membrane, leading to ROS production [58]. Further-
more, the elongation of VLCFA, which is located in the 
ER, is increased in X-ALD fibroblasts [50, 68], perhaps 
contributing to the UPR. In other cases, lipid disequilib-
rium within the ER membrane could influence the quan-
tity and trafficking of misfolded proteins in the ER lumen, 
leading indirectly to the activation of UPR transducers [33, 
97]. All in all, and in the absence of direct proof of protein 
aggregates in the ER lumen, we posit that ER membrane 
lipid perturbation induced by VLCFA accumulation leads 
to UPR transducer activation, allowing the cell to adapt the 
ER folding and ERAD machinery igniting an “anticipatory 
ER stress” response [80, 96] (Fig. 7).
A modification of the ER membrane fluidity by fatty 
acids is of direct relevance to diseases that are associated 
with increases in saturated fatty acids, such as non-alcoholic 
fatty liver [8, 77] or type 2 diabetes mellitus [70], which 
also show ER stress in the absence of misfolded proteins.
Regarding the timing of the observed responses, we 
observed that in X-ALD and the models of PDB or single 
peroxisomal enzyme deficiencies, UPR activation occured 
early in life [23, 45, 53]. In contrast, UPR activation is not 
an early event in AD [52], Tau disease [39, 52], PD [12, 13] 
or ALS [51]. We thus hypothesize that late UPR activation, 
such as that for AD or PD when compared with that for 
peroxisomal disorders may be related to the phenomenon 
of deteriorating peroxisomal fitness over time, as observed 
during ageing and neurodegenerative disorders [5, 21, 32, 
63, 89]. Altogether, these data suggest that an altered per-
oxisomal function and subsequent lipid metabolism unbal-
ance are key contributors to ER stress, both in rare and 
common neurodegenerative disorders.
Bile acids in the treatment of neurodegenerative 
disorders?
The relevance of bile acids for brain function is illustrated 
by the observation of large amounts of several intermedi-
ates of bile acid biosynthesis in the cerebrospinal fluid 
[69] (Supplemental Fig. S6). Three of them (glycocholate, 
glycodeoxycholate, and glycochenodeoxycholate) were 
elevated in the plasma of AD patients [90], and other com-
pounds of this route were found to be altered in X-ALD 
adult patients. 5β-cholestane-3α,7α,12α-triol, cholate 
and glycolate are accumulated in the plasma, whereas 
5β-cholestane-3α,7α,12α,26-tetrol is increased in periph-
eral blood mononuclear cells from AMN patients [79]. 
Pex2−/− mice also showed an accumulation of the toxic 
THCA and DHCA in liver tissue, which was concomitant 
with ER stress [49, 53].
UDCA [15] and TUDCA [70, 72] are hydrophilic bile 
acids that have been used to alleviate ER stress. TUDCA 
is of particular interest because its levels are lowered in 
Pex2−/− mice [25], thereby suggesting a contribution to 
ER stress. Indeed, a diet that is enriched in cholic acid and 
UDCA was able to improve the dendritic arborization of 
cerebellar Purkinje cells in vivo [22], while also increas-
ing both UDCA and TUDCA levels [49]. Moreover, the 
chronic administration of UDCA and TUDCA is able 
to modify the lipid and fatty acid composition of the ER 
membrane in the rat liver [4]. Treatment with TUDCA has 
also been shown to ameliorate ER stress in AD [17] and 
PD mouse models [10]. Altogether, these data suggest that 
UPR activation may be the result of an alteration in ER 
membrane fluidity, as noted above, which may be alleviated 
by replenishing TUDCA levels. We thus posit that levels of 
bile acids, including TUDCA and fatty acids, are impor-
tant in ER stress-related disorders and that it is advisable to 
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include drugs that seek to restore their normal levels when 
managing these diseases.
Although a systematic comparison of neurodegenerative 
diseases that highlights therapeutically relevant similarities 
and differences is still lacking, our data reinforce the notion 
that ER dysfunction is a pivotal, actionable target for treat-
ing neurodegenerative diseases [82]. Interestingly, here we 
demonstrated that the treatment of X-ALD mice with the ER 
stress inhibitor TUDCA reduced the progression of axonal 
degeneration and locomotor disabilities (Fig. 6). This finding 
is highly relevant because it provides a feasible therapeutic 
avenue for correcting peroxisomal disorders and neurode-
generative diseases. Indeed, TUDCA has outstanding in vivo 
safety profiles, is able to cross the blood–brain barrier, and has 
been approved by the U.S. Food and Drug Administration for 
clinical use [37]. Clinical trials for ALS and HD have recently 
been conducted and have yielded promising results regard-
ing safety and efficacy (NCT00877604; NCT00514774) [20, 
60, 71]. Thus, we believe that for diseases in which ER stress 
is an early factor in the pathogenetic cascade, the chances of 
success may be even greater.
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